Publicaciones en las que colabora con Eva M. Carro Díaz (10)

2022

  1. Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer’s Disease Patients

    Frontiers in Immunology, Vol. 13

  2. Saliva is a Good Candidate to be the New Gold-Standard Sample for Neurodegenerative Diseases

    Journal of Alzheimer's Disease, Vol. 87, Núm. 4, pp. 1497-1501

2021

  1. Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for alzheimer’s disease

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 13, Núm. 1

2020

  1. Decreased salivary lactoferrin levels are specific to Alzheimer's disease

    EBioMedicine, Vol. 57, pp. 102834

2017

  1. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 8, pp. 131-138

2015

  1. Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease

    Journal of Controlled Release, Vol. 203, pp. 170-180

2014

  1. Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model

    Neurobiology of Aging, Vol. 35, Núm. 7, pp. 1582-1595

2013

  1. Intranasal Delivery of Plasma and Platelet Growth Factors Using PRGF-Endoret System Enhances Neurogenesis in a Mouse Model of Alzheimer's Disease

    PLoS ONE, Vol. 8, Núm. 9

2012

  1. Encapsulated VEGF-secreting cells enhance proliferation of neuronal progenitors in the hippocampus of AβPP/PS1 mice

    Journal of Alzheimer's Disease, Vol. 29, Núm. 1, pp. 187-200

2010

  1. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease

    Biomaterials, Vol. 31, Núm. 21, pp. 5608-5618